RSS   Newsletter   Contact   Advertise with us
Post Online Media

Martin Duvall appointed as chief executive officer of Tocagen

Martin DuvallTocagen Inc., a clinical-stage, cancer-selective gene therapy company, announced the appointment of Martin Duvall as chief executive officer and member of the company’s board of directors.

Mr. Duvall holds more than 30 years of experience in oncology drug development and commercialization at mid-stage and global pharmaceutical companies, including building numerous successful oncology teams.

READ MORE Tocagen appoints Paul Schimmel to the board of directors

Prior to joining Tocagen he served as executive vice president, chief commercial officer of ARIAD Pharmaceuticals, and helped lead the company’s transformation into a fully integrated, global biotechnology company.

Previous to Mr. Duvall’s role at ARIAD, he served as senior vice president and general manager, oncology, at Merck and & Co., Inc.

Prior to this role, Mr. Duvall was the senior vice president, global marketing and commercial operations at Abraxis Bioscience, Inc. (acquired by Celgene), where he guided global commercial strategy for Abraxane.

Prior to joining Abraxis, he was the senior vice president, commercial operations, for MGI Pharma, Inc. (acquired by Eisai Co., Ltd.), where he held a key role in the launch and commercialization of Aloxi.

Previous to MGI, Mr. Duvall held roles of increasing responsibility related to commercialization, marketing and sales of oncology drugs at Sanofi and its predecessor companies.

Mr. Duvall holds a master’s degree in chemistry from Johns Hopkins University, master’s degree in business from The University of Kansas and bachelor’s degree in chemistry from Muhlenberg College.

Harry Gruber, M.D., who previously served as Tocagen’s chief executive officer, has assumed the role of president, research and development, and will remain a member of Tocagen’s board of directors.


 LATEST MOVES FROM California 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy